ArticleWorld journal of stem cells2025
Melanoma cell adhesion molecule-positive mesenchymal stromal cells alleviate acute respiratory distress syndrome
Article in World journal of stem cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Harnessing CD146-positive mesenchymal stromal cells for precision therapy in acute respiratory distress syndrome.World journal of stem cells · 2026Article
- CD146-positive mesenchymal stromal cells: A promising subtype for enhanced acute respiratory distress syndrome therapy.World journal of stem cells · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMesenchymal stromal cells (MSCs) are renowned for their immunosuppressive properties, which make them widely used in managing excessive inflammation. Although CD146+ and CD146- MSCs exhibit similar morphological traits and surface marker expression levels, the specific characteristics and differential regulatory mechanisms of these two subtypes remain poorly understood. This knowledge gap has limited the precise application of MSCs in targeted therapeutic strategies.
aimTo compare the functional differences between CD146+ and CD146- MSCs and investigate the underlying mechanisms.
methodsIn this study, magnetic beads were used to sort umbilical cord-derived MSCs into CD146+ and CD146- subsets. The pro-angiogenic factors (hepatocyte growth factor, prostaglandin E2, vascular endothelial growth factor, angiopoietin-1) production and immunomodulatory effects on T lymphocyte subsets were evaluated
resultsCytokine secretion and angiogenesis: CD146+ MSCs significantly increased the production of hepatocyte growth factor, prostaglandin E2, vascular endothelial growth factor, and angiopoietin-1 and exhibited increased pro-angiogenic activity
conclusionCD146+ MSCs show stronger ARDS therapeutic potential than CD146- MSCs
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.